Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548868 | 0.88 | CA12 (0.44) | CA12CA1CA9CA2CA7 | |
| SCHEMBL13640332 | 0.84 | CA12 (0.59) | CA12CA1CA9CA2CA7 | |
| SCHEMBL21083328 | 0.83 | CA12 (0.42) | CA12CA1CA9CA2CA7 | |
| SCHEMBL8162618 | 0.83 | CA12 (0.45) | CA12CA1CA9PREP | |
| SCHEMBL4598948 | 0.82 | KDM4E (0.42) | CA12CA1CA9CA7CA14 | |
| SCHEMBL1056366 | 0.80 | ALOX5AP (0.36) | CA12CA1CA9CA14 | |
| SCHEMBL29562217 | 0.79 | ACHE (0.36) | CA12CA1CA9KMT2ASMN1; SMN2 | |
| SCHEMBL15085977 | 0.79 | APLNR (0.45) | CA12CA1CA9ALDH1A1KMT2A | |
| SCHEMBL14726038 | 0.79 | ACHE (0.36) | CA12CA1CA9KMT2ASMN1; SMN2 | |
| SCHEMBL16536257 | 0.78 | ALDH1A1 (0.42) | CA12CA1CA9CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4660182-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING ARYL PYRIDINE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024159285-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING ARYL PYRIDINE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2024-08-08 | — | — | WO | disclosed |
| EP-2571862-B1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| EP-2571862-B1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8436009-B2 | Prodrug of triazolone compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8436009-B2 | Prodrug of triazolone compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-07 | — | — | US | disclosed |
| EP-2571862-A1 | PRODRUG OF TRIAZOLONE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-28 | — | — | US | disclosed |
| WO-2011145747-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | F7, TFPI, TFPI2 | CA12 3914/4885CA1 2145/4885CA9 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.